Use of Levosimendan as bridge therapy to surgical correction of post-infarction ventricular septal defect: a case report

Eur Rev Med Pharmacol Sci. 2021 Apr;25(8):3296-3299. doi: 10.26355/eurrev_202104_25739.

Abstract

Objective: Ventricular septal defect (VSD) is an uncommon but frequently fatal complication following acute myocardial infarction. In medically treated patients, mortality rates exceed 90%, while the surgical repair is associated with better outcomes, even though optimal surgical timing is still under debate.

Case report: We present the case of a 78-years-old man with no previous remarkable cardiological history admitted to our Emergency Department with the diagnosis of anterior ST-elevation myocardial infarction and significant reduction of left ventricular ejection fraction. The emergency coronary angiography showed sub-occlusion of the left anterior descending coronary artery, treated with stent implantation. The post-procedural echocardiography unveiled the presence of an apical VSD with a large left-to-right shunt, significant right ventricular overload and dysfunction. An intra-aortic balloon pump (IABP) was positioned and, after Heart Team evaluation, a delayed surgical approach was planned. As a bridge to the intervention Levosimendan infusion was administered, on top of IABP support, and a significant improvement in bi-ventricular function and pressure profiles was obtained. Cardiac surgery was successfully performed 9 days after the admission without periprocedural complications.

Conclusions: This unique case supports the use of Levosimendan as a valid pharmacological strategy for perioperative management of VSD.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Cardiac Surgical Procedures
  • Humans
  • Male
  • Simendan / administration & dosage
  • Simendan / therapeutic use*
  • Ventricular Septal Rupture / diagnosis
  • Ventricular Septal Rupture / drug therapy*
  • Ventricular Septal Rupture / surgery

Substances

  • Simendan